AstraZeneca in a jam after drug setback

Article Abstract:

Europe's third largest drug maker AstraZeneca is in a jam after the Food and Drug Administration Advisory Committee felt the drug Exanta was risky for the liver and heart and the risk outweighed its benefits in preventing blood clots. The company has to undertake extensive new patients study to prove the drug's safety or it could end its development following which the share prices could fall, as the drug did not receive approval from regulators.

United Kingdom, Product development, Management dynamics, Management, AstraZeneca PLC, Company business management, United States. Food and Drug Administration, AZN, Exanta (Medication)

---

Cephalon is winner in battle for Cima

Article Abstract:

West Chester-based Cephalon Inc. agreed to buy Cima Laboratories Inc., Minnesota specialist in drug-delivery technology, for $34 a share in cash in 2003. Cephalon's offer won over those made by aaiPharma Inc. in Wilmington, and an unidentified company.

Acquisitions & mergers, CHEMICALS AND ALLIED PRODUCTS, Mergers, acquisitions and divestments, Company acquisition/merger, Chemical industry, Pesticides industry, Herbicides, Cephalon Inc., CEPH, Sulphur industry, CIMA LABS Inc.

---

Vaccine plant to triple output

Article Abstract:

The MedImmunes Vaccines Inc. plant in Northeast Philadelphia has raised production from 1 million to 3.1 million doses amid the severe shortage of vaccines. The Philadelphia plant is using leftover FluMist bulk concentrate sent from Speke, England.

Production management, Capacity, MedImmune Vaccines

Similar abstracts:

• Abstracts: American Home's diet-drug settlement is attacked. Calif. firm to acquire drugmaker. Glaxo-SmithKline deal
• Abstracts: Political braches open in every county. Investment bank hired to study PGW. Tab for Stadiums: $1.2 Billion
• Abstracts: MBNA's lending fell in 1st quarter. Bank founder settle lawsuit. Former U.S. Bancorp official to lead First USA
• Abstracts: Top local banker retiring early. PNC Bank to conduct campaign to cut costs. Juniper planning online banking
• Abstracts: Lowe's presence to grow in area. Group has plan to lure biotech research here. Outlook revised upward for Penn bonds

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.